<DOC>
	<DOCNO>NCT02007005</DOCNO>
	<brief_summary>The aim phase Ib/IIa study investigate maximum tolerable concentration abnobaVISCUM® Fraxini intravesical instillation patient superficial bladder cancer . Secondary objective local systemic tolerability , influence tumor remission influence one-year recurrence rate .</brief_summary>
	<brief_title>Maximum Tolerable Concentration abnobaVISCUM Fraxini Intravesically Patients With Superficial Bladder Cancer</brief_title>
	<detailed_description>A dose-escalation-study accord ICH/GCP ( International Conference Harmonisation/Good Clinical Practice ) different concentration abnobaVISCUM® Fraxini conduct two hospital Germany Egypt . Patients superficial bladder cancer TaG1/G2 T1G1/G2 enclose TUR-B ( transurethral resection bladder ) . The tolerability different concentration assess weekly instillation urinary bladder 6 week . A direct antitumoral effect assess single marker tumor leave bladder complete TUR lesion accord study design establish EORTC-GENITO-URINARY GROUP ( European Organisation Research Treatment Cancer ) . A re-TUR conducted 12 week . Tumor response measure biopsy marker lesion cytology . Safety instillation measure analysis adverse event , vital sign clinical laboratory test . After treatment cohort finish safety evaluation conduct decide increase next dosage .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>Patients clinically prove superficial bladder cancer ( Ta G1/G2 T1G1/G2 ) 2 7 week transurethral resection Written inform consent study participation documentation disease data include distribution data Muscle invasive bladder carcinoma and/or carcinoma situ ( CIS ) Intravesical instillation therapy within 6 month prior study enrolment Radiotherapy bladder prior study enrolment Contracted bladder ( capacity le 100 ml ) Non treat acute chronic urinary tract infection Allergy mistletoe extract preparation Subvesical obstruction ( e. g. prostate hyperplasia , urethral stenosis , residual urine volume 80 ml ) Severe illnesses circumstance permit study participation ( e. g. alcoholism substance abuse ) Pregnancy lactation ( pregnancy test require ) well woman without sufficient contraception Participation another clinical study within 30 day prior study Administration immunotherapeutic and/or cytostatic drug within 4 week prior study enrolment Chronic progressive infection ( e. g. tuberculosis ) Pretreatment mistletoe extracts/mistletoe lectin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>superficial bladder cancer</keyword>
	<keyword>mistletoe extract</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>marker tumor</keyword>
	<keyword>remission</keyword>
	<keyword>recurrence rate</keyword>
</DOC>